Boston Scientific Corporation

Symbol: BSX

NYSE

74.1

USD

Market price today

  • 61.4390

    P/E Ratio

  • 0.6961

    PEG Ratio

  • 108.94B

    MRK Cap

  • 0.00%

    DIV Yield

Boston Scientific Corporation (BSX) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.69%

Operating Profit Margin

0.17%

Net Profit Margin

0.12%

Return on Assets

0.05%

Return on Equity

0.09%

Return on Capital Employed

0.08%

Company general description and statistics

Sector: Healthcare
Industry: Medical - Devices
CEO:Mr. Michael F. Mahoney
Full-time employees:48000
City:Marlborough
Address:300 Boston Scientific Way
IPO:1992-05-19
CIK:0000885725

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

General Outlook

When we look at how much money they make before expenses, they keep 0.691% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.169%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.120%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.048% return, is a testament to Boston Scientific Corporation's adeptness in optimizing resource deployment. Boston Scientific Corporation's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.093%. Furthermore, the proficiency of Boston Scientific Corporation in capital utilization is underscored by a remarkable 0.078% return on capital employed.

Liquidity Ratios

Analyzing BSX liquidity ratios reveals its financial health of the firm. The current ratio of 166.50% gauges short-term asset coverage for liabilities. The quick ratio (129.43%) assesses immediate liquidity, while the cash ratio (47.38%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio166.50%
Quick Ratio129.43%
Cash Ratio47.38%

Profitability Ratios

BSX profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 14.61% underscores its earnings before tax deductions. The effective tax rate stands at 17.54%, revealing its tax efficiency. The net income per EBT, 82.41%, and the EBT per EBIT, 86.51%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 16.89%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin14.61%
Effective Tax Rate17.54%
Net Income per EBT82.41%
EBT per EBIT86.51%
EBIT per Revenue16.89%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.66, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding129
Days of Inventory Outstanding206
Operating Cycle263.17
Days of Payables Outstanding74
Cash Conversion Cycle189
Receivables Turnover6.38
Payables Turnover4.93
Inventory Turnover1.77
Fixed Asset Turnover4.42
Asset Turnover0.40

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 1.69, and free cash flow per share, 1.06, depict cash generation on a per-share basis. The cash per share value, 2.76, showcases liquidity position. A payout ratio of 0.01 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.17, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share1.69
Free Cash Flow per Share1.06
Cash per Share2.76
Payout Ratio0.01
Operating Cash Flow Sales Ratio0.17
Free Cash Flow to Operating Cash Flow Ratio0.63
Cash Flow Coverage Ratio0.23
Short Term Coverage Ratio2.28
Capital Expenditure Coverage Ratio2.68
Dividend Paid and Capex Coverage Ratio2.64

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 30.00%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.55, we discern the balance between debt and equity financing. The long-term debt to capitalization, 33.23%, and total debt to capitalization, 35.57%, ratios shed light on its capital structure. An interest coverage of 9.20 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio30.00%
Debt Equity Ratio0.55
Long Term Debt to Capitalization33.23%
Total Debt to Capitalization35.57%
Interest Coverage9.20
Cash Flow to Debt Ratio0.23
Company Equity Multiplier1.84

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 9.80, provides a glimpse into top-line earnings distributed across each share. Net income per share, 1.10, reflects the portion of profit attributed to each share. The book value per share, 13.27, represents the net asset value distributed per share, while the tangible book value per share, -0.59, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share9.80
Net Income Per Share1.10
Book Value Per Share13.27
Tangible Book Value Per Share-0.59
Shareholders Equity Per Share13.27
Interest Debt Per Share6.72
Capex Per Share-0.55

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 12.29%, indicates top-line expansion, while the gross profit growth, 14.01%, reveals profitability trends. EBIT growth, 42.09%, and operating income growth, 42.09%, offer insights into operational profitability progression. The net income growth, 128.22%, showcases bottom-line expansion, and the EPS growth, 140.00%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth12.29%
Gross Profit Growth14.01%
EBIT Growth42.09%
Operating Income Growth42.09%
Net Income Growth128.22%
EPS Growth140.00%
EPS Diluted Growth137.78%
Weighted Average Shares Growth1.57%
Weighted Average Shares Diluted Growth1.65%
Dividends per Share Growth-49.88%
Operating Cash Flow Growth64.02%
Free Cash Flow Growth86.32%
10-Year Revenue Growth per Share84.02%
5-Year Revenue Growth per Share37.78%
3-Year Revenue Growth per Share40.06%
10-Year Operating CF Growth per Share113.53%
5-Year Operating CF Growth per Share667.41%
3-Year Operating CF Growth per Share61.83%
10-Year Net Income Growth per Share1315.23%
5-Year Net Income Growth per Share-9.39%
3-Year Net Income Growth per Share1209.43%
10-Year Shareholders Equity Growth per Share172.17%
5-Year Shareholders Equity Growth per Share110.04%
3-Year Shareholders Equity Growth per Share22.65%
3-Year Dividend per Share Growth per Share-2.50%
Receivables Growth13.10%
Inventory Growth33.05%
Asset Growth8.21%
Book Value per Share Growth8.01%
Debt Growth2.26%
R&D Expense Growth6.88%
SGA Expenses Growth14.82%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 92,624,930,000, captures the company's total value, considering both debt and equity. Income quality, 1.57, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 58.03%, indicates the value of non-physical assets, and capex to operating cash flow, -31.96%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value92,624,930,000
Income Quality1.57
Research and Development to Revenue9.93%
Intangibles to Total Assets58.03%
Capex to Operating Cash Flow-31.96%
Capex to Revenue-5.62%
Capex to Depreciation-66.89%
Stock-Based Compensation to Revenue1.64%
Graham Number18.09
Return on Tangible Assets10.80%
Graham Net Net-8.14
Working Capital1,581,000,000
Tangible Asset Value-860,000,000
Net Current Asset Value-9,092,000,000
Average Receivables2,099,000,000
Average Payables902,000,000
Average Inventory2,175,500,000
Days Sales Outstanding57
Days Payables Outstanding79
Days of Inventory On Hand209
ROIC6.53%
ROE0.08%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 5.46, and the price to book ratio, 5.46, reflect the market's valuation relative to the company's book value. The price to sales ratio, 7.41, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 70.15, and price to operating cash flows, 43.93, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio5.46
Price to Book Ratio5.46
Price to Sales Ratio7.41
Price Cash Flow Ratio43.93
Price Earnings to Growth Ratio0.70
Enterprise Value Multiple27.73
Price Fair Value5.46
Price to Operating Cash Flow Ratio43.93
Price to Free Cash Flows Ratio70.15
Price to Tangible Book Ratio4.36
Enterprise Value to Sales6.50
Enterprise Value Over EBITDA25.59
EV to Operating Cash Flow37.01
Earnings Yield1.90%
Free Cash Flow Yield2.03%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Boston Scientific Corporation (BSX) on the NYSE in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 61.439 in 2024.

What is the ticker symbol of Boston Scientific Corporation stock?

The ticker symbol of Boston Scientific Corporation stock is BSX.

What is company IPO date?

IPO date of Boston Scientific Corporation is 1992-05-19.

What is company current share price?

Current share price is 74.100 USD.

What is stock market cap today?

The market cap of stock today is 108940338000.000.

What is PEG ratio in 2024?

The current 0.696 is 0.696 in 2024.

What is the number of employees in 2024?

In 2024 the company has 48000.